newsfilter
← Latest News
GlobeNewswire·

Indaptus Therapeutics Provides Clinical Update

Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW